Mirabegron: Difference between revisions
No edit summary |
Carlo Banez (talk | contribs) - link to FDA information |
||
| Line 8: | Line 8: | ||
<!-- Clinical data --> |
<!-- Clinical data --> |
||
| tradename = Myrbetriq, Betanis |
| tradename = Myrbetriq, Betanis |
||
| licence_US = Mirabegron |
|||
| Drugs.com = |
| Drugs.com = |
||
| MedlinePlus = |
| MedlinePlus = |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = |
| pregnancy_US = C |
||
| pregnancy_category= |
| pregnancy_category= |
||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
||
| legal_US = |
| legal_US = Rx-only |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = Oral |
||
<!-- Pharmacokinetic data --> |
<!-- Pharmacokinetic data --> |
||
Revision as of 13:48, 9 November 2012
{{Drugbox | drug_name = Mirabegron | IUPAC_name = 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide | image = Mirabegron.svg | alt = | caption =
| tradename = Myrbetriq, Betanis | licence_US = Mirabegron | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = C | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Oral
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
| CAS_number = 223673-61-8 | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = 9865528 | ChemSpiderID = 8041219 | DrugBank = | synonyms = YM-178
| chemical_formula = C21H24N4O2S | molecular_weight = 396.506 g/mol | SMILES = O=C(Nc1ccc(cc1)CCNC[C@H](O)c2ccccc2)Cc3nc(sc3)N | InChI = 1/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1 | InChIKey = PBAPPPCECJKMCM-IBGZPJMEBA | StdInChI = 1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1 | StdInChIKey = PBAPPPCECJKMCM-IBGZPJMESA-N }}
Mirabegron (formerly YM-178, trade name Myrbetriq) is a drug for the treatment of overactive bladder.[1] It was developed by Astellas Pharma and was approved in the United States in July 2012.
Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.[2]
References
- ^ Gras, J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of today (Barcelona, Spain : 1998). 48 (1): 25–32. doi:10.1358/dot.2012.48.1.1738056. PMID 22384458.
- ^ "New Drug Approvals 2012 - Pt. XIV - Mirabegron (MyrbetriqTM)". ChEMBL. 5 July 2012. Retrieved 28 September 2012.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |